A new study offers a nuanced look at immunotherapy for rare gynecologic cancers, specifically clear cell carcinomas (CCCs) of the ovary, endometrium and cervix. These cancers are often aggressive and don’t respond well to traditional chemotherapy, creating an urgent need for alternative treatments. Researchers are exploring whether combining two types of immunotherapy drugs – nivolumab and ipilimumab – can offer a durable benefit for patients, even if initial response rates are modest. The findings, from the DART (SWOG S1609) Phase II trial, suggest that while not every patient responds, those who do may experience long-lasting remission, particularly in cases of ovarian CCC.
The DART trial, a multicenter study designed to evaluate treatments for rare tumors, enrolled 32 patients with gynecologic CCC who had already undergone extensive prior treatment – with a median of 1 to 8 previous lines of therapy, including prior exposure to PD-1 inhibitors for three patients. The treatment regimen involved administering nivolumab every two weeks and ipilimumab every six weeks. The primary goal was to assess the overall response rate (ORR) based on standard RECIST criteria, but researchers as well tracked progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR), and safety.
Durability Signals in Ovarian Cancer
The overall response rate across the entire cohort was 9.38% (3 out of 32 patients), consisting of two complete responses and one partial response. However, the study revealed a significant pattern: both complete responses were observed in patients with ovarian clear cell carcinoma, and these remissions have remained ongoing for more than three years. This durability is a key finding, suggesting that a subset of patients with this specific cancer subtype may experience a profound and lasting benefit from the combination therapy. When researchers used immune-related RECIST (iRECIST) criteria, the ORR increased to 12.5% (4 out of 32), with one patient with cervical CCC achieving a partial response lasting 26 months and an overall survival of 32 months.
Beyond Response Rate: Clinical Benefit and Safety
Researchers also examined the clinical benefit rate (CBR), which considers both response and stable disease lasting at least six months. The CBR was 21.88% (7 out of 32 patients), indicating that roughly one in five patients experienced meaningful and sustained disease control. This benefit was most pronounced in the ovarian and cervical cancer subgroups. The median overall survival for the entire cohort was 21.7 months, though outcomes varied considerably. While endometrial CCC showed limited activity in this study, ovarian CCC demonstrated the most promising results.
The treatment wasn’t without side effects. Grade 3 or higher adverse events potentially related to the treatment occurred in 53% of patients (17 out of 32), leading to treatment discontinuation in 22% (7 out of 32). However, there were no treatment-related deaths. Common adverse events included elevated liver enzymes, anemia, and nausea, consistent with the known immune-related toxicities associated with dual checkpoint therapy.
Understanding the Findings in Context
The researchers noted that the lower overall response rate observed in the DART trial, compared to some other studies of dual checkpoint blockade in clear cell carcinoma, may be attributable to the fact that this cohort had received a high degree of prior treatment – up to eight prior lines of therapy, with some patients having previously been exposed to PD-1 inhibitors. Prior treatment and PD-1 exposure can reduce the likelihood of response, even if long-term durability remains possible. The study underscores the importance of identifying biomarkers that can predict which patients are most likely to benefit from this type of immunotherapy. Further research is needed to refine treatment strategies and optimize dosing schedules to minimize toxicity while maximizing efficacy.
The full article detailing the DART trial findings is available here.
This research highlights the potential of combination immunotherapy to provide durable benefits for a subset of patients with gynecologic clear cell carcinoma, particularly those with ovarian cancer. While challenges remain in identifying the right patients and managing treatment-related toxicities, the prospect of long-term remission offers hope for this difficult-to-treat disease. Future studies will focus on identifying biomarkers to better predict response and refine treatment strategies. The next steps involve further analysis of patient samples to understand the underlying mechanisms of response and resistance to immunotherapy in these cancers.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have thoughts on this research? Share your comments below, and please share this article with your network.
